PT - JOURNAL ARTICLE AU - Mao, Andrew AU - Flassbeck, Sebastian AU - Marchetto, Elisa AU - Masurkar, Arjun V. AU - Rusinek, Henry AU - Assländer, Jakob TI - Sensitivity of unconstrained quantitative magnetization transfer MRI to Amyloid burden in preclinical Alzheimer’s disease AID - 10.1101/2024.04.15.24305860 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.15.24305860 4099 - http://medrxiv.org/content/early/2024/07/07/2024.04.15.24305860.short 4100 - http://medrxiv.org/content/early/2024/07/07/2024.04.15.24305860.full AB - Magnetization transfer MRI is sensitive to semi-solid macromolecules, including amyloid beta, and has previously been used to discriminate Alzheimer’s disease (AD) patients from controls. Here, we fit an unconstrained 2-pool quantitative MT (qMT) model, i.e., without constraints on the longitudinal relaxation rate of semi-solids, and investigate the sensitivity of the estimated parameters to amyloid accumulation in preclinical subjects. We scanned 15 cognitively normal volunteers, of which 9 were amyloid positive by [18F]Florbetaben PET. A 12 min hybrid-state qMT scan with an effective resolution of 1.24 mm isotropic and whole-brain coverage was acquired to estimate the unconstrained 2-pool qMT parameters. Group comparisons and correlations with Florbetaben PET standardized uptake value ratios were analyzed at the lobar level. We find that the exchange rate and semi-solid pool’s were sensitive to the amyloid concentration, while morphometric measures of cortical thickness derived from structural MRI were not. Changes in the exchange rate are consistent with previous reports in clinical AD, while changes in have not been reported previously as its value is typically constrained in the literature. Our results demonstrate that qMT MRI may be a promising surrogate marker of amyloid beta without the need for contrast agents or radiotracers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH grants F30 AG077794, R01 NS131948, T32 GM136573, an NIA-funded Alzheimer's Disease Research Center (P30 AG066512), and was performed under the rubric of the Center for Advanced Imaging Innovation and Research (CAI2R), an NIBIB National Center for Biomedical Imaging and Bioengineering (P41 EB017183).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the New York University School of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesN/A